In this interview, Yehuda Handelsman, MD, highlights key updates to the Diabetes, Cardiorenal, and Metabolic (DCRM) guidelines in DCRM 2.0, shaped by global collaboration and recent clinical insights.

On December 5, 2024, the U.S. Food and Drug Administration (“FDA”) issued a much anticipated draft guidance for industry on accelerated approval ...

The challenges and innovative solutions to spreading evidence-based medical research across China in order to improve the ...

USA: The World Health Organization (WHO) has issued updated guidelines on the administration of oxytocin for the prevention ...

Clinical research plays a vital role in modern medicine, leading to the development of new treatments and medical ...

In today’s edition…An international initiative aims to tackle bias in medical AI algorithms; Europe’s privacy regulators say ...

A recently published, comprehensive systematic review and meta-analysis has added to the growing body of evidence showing ...

The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to ...

Cystic fibrosis, a genetic disease that attacks the lungs, affects roughly 1 in 3,000 people, and cystic fibrosis-related ...

GP practices are facing confusion over different approaches to asthma diagnosis set out in the QOF and in the new UK joint ...

Sun, Y. , Cheng, X. and Pen, K. (2024) Clinical Value of Platelet-Related Parameters and Monocyte Counts in Patients with ...

Myriad Genetics, Inc. MYGN is driving innovation across Oncology, Women's Health and Pharmacogenomics, and heavily invests in labs and digital capabilities. Thecompany’s Oncology growth strategy ...